6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
greater O
than O
or O
equal O
to O
10 O
% O
, O
all O
grades O
) O
observed O
with O
treatment O
with O
HARVONI O
for O
8 O
, O
12 O
, O
or O
24 O
weeks O
are O
fatigue O
and O
headache O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Gilead O
Sciences O
, O
Inc O
. O
at O
1-800-GILEAD-5 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
assessment O
of O
HARVONI O
was O
based O
on O
pooled O
data O
from O
three O
Phase O
3 O
clinical O
trials O
of O
subjects O
with O
genotype B-Not_AE_Candidate
1 I-Not_AE_Candidate
chronic I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
C I-Not_AE_Candidate
( I-Not_AE_Candidate
CHC I-Not_AE_Candidate
) O
with O
compensated B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
with I-Not_AE_Candidate
and I-Not_AE_Candidate
without I-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
) O
including O
215 O
, O
539 O
, O
and O
326 O
subjects O
who O
received O
HARVONI O
for O
8 O
, O
12 O
and O
24 O
weeks O
, O
respectively O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
0 O
% O
, O
< O
1 O
% O
, O
and O
1 O
% O
for O
subjects O
receiving O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
) O
were O
fatigue B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
in O
subjects O
treated O
with O
8 O
, O
12 O
, O
or O
24 O
weeks O
of O
HARVONI O
. O

Table O
2 O
lists O
adverse O
reactions O
( O
adverse O
events O
assessed O
as O
causally O
related O
by O
the O
investigator O
, O
all O
grades O
) O
observed O
in O
> O
=5 O
% O
of O
subjects O
receiving O
8 O
, O
12 O
, O
or O
24 O
weeks O
treatment O
with O
HARVONI O
in O
clinical O
trials O
. O

The O
majority O
of O
adverse O
reactions O
presented O
in O
Table O
2 O
occurred O
at O
severity O
of O
grade O
1 O
. O

The O
side-by-side O
tabulation O
is O
to O
simplify O
presentation O
; O
direct O
comparison O
across O
trials O
should O
not O
be O
made O
due O
to O
differing O
trial O
designs O
. O

Table O
2 O
Adverse O
Reactions O
( O
All O
Grades O
) O
Reported O
in O
> O
=5 O
% O
of O
Subjects O
Receiving O
8 O
, O
12 O
, O
or O
24 O
Weeks O
of O
Treatment O
with O
HARVONI O
HARVONI8 O
weeks O
HARVONI12 O
weeks O
HARVONI24 O
weeks O
N=215 O
N=539 O
N=326 O
Fatigue B-OSE_Labeled_AE
16 O
% O
13 O
% O
18 O
% O
Headache B-OSE_Labeled_AE
11 O
% O
14 O
% O
17 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
7 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
4 O
% O
3 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
3 O
% O
5 O
% O
6 O
% O
Laboratory O
Abnormalities O
Bilirubin B-NonOSE_AE
Elevations I-NonOSE_AE
: O
Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
greater O
than O
1.5*ULN O
were O
observed O
in O
3 O
% O
, O
< O
1 O
% O
, O
and O
2 O
% O
of O
subjects O
treated O
with O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

Lipase B-NonOSE_AE
Elevations I-NonOSE_AE
: O
Transient O
, O
asymptomatic O
lipase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
greater O
than O
3*ULN O
were O
observed O
in O
< O
1 O
% O
, O
2 O
% O
, O
and O
3 O
% O
of O
subjects O
treated O
with O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

Creatine B-NonOSE_AE
Kinase I-NonOSE_AE
: O
Creatine B-NonOSE_AE
kinase I-NonOSE_AE
was O
not O
assessed O
in O
Phase O
3 O
trials O
of O
HARVONI O
. O

Isolated O
, O
asymptomatic O
creatine B-NonOSE_AE
kinase I-NonOSE_AE
elevations I-NonOSE_AE
( O
Grade O
3 O
or O
4 O
) O
have O
been O
previously O
reported O
in O
subjects O
treated O
with O
sofosbuvir O
in O
combination O
with O
ribavirin O
or O
peginterferon/ribavirin O
in O
other O
clinical O
trials O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
HARVONI O
. O

Because O
postmarketing O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Serious O
symptomatic O
bradycardia B-NonOSE_AE
has O
been O
reported O
in O
patients O
taking O
amiodarone O
who O
initiate O
treatment O
with O
HARVONI O
[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O

